CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 450 enrolled
Drug / intervention
Sirolimus eluting stent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00598715
NCT00598715Phase 4Completed
CompareCT.gov

Randomized Trial of Paclitaxel- vs Sirolimus-eluting Stents for Treatment of Coronary Restenosis in Sirolimus-eluting Stents

Deutsches Herzzentrum Muenchen·interventional·Posted Jan 22, 2008·Updated Dec 17, 2010

In Brief

A Phase 4 clinical trial evaluating Sirolimus eluting stent and Paclitaxel-eluting stent for Coronary Artery Disease. Completed, enrolled 450 participants across 2 sites.

Detailed Summary

For lesions which develop restenosis after a drug-eluting stent, it is not known which the right strategy to use is, implantation of the same type of DES as the initial one or a DES with a different drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesGermany
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 22, 2008
Enrollment StartOct 1, 2007
Primary CompletionAug 1, 2009
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 18.4 years ago

Interventions

Sirolimus eluting stentdevice

Sirolimus-eluting stent will be implanted

Paclitaxel-eluting stentdevice

Paclitaxel-eluting stent will be implanted